Analysis of predictive biomarkers in patients with lung adenocarcinoma from Southern Brazil reveals a distinct profile from other regions of the country
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/232208 |
Resumo: | PURPOSE Adenocarcinoma is the most common histologic subtype of non–small-cell lung cancer, representing 40% of all diagnoses. Several biomarkers are currently used to determine patient eligibility for targeted treatments, including analysis of molecular alterations in EGFR and ALK, as well as programmed death-ligand 1 (PD-L1) protein expression. Epidemiologic data reporting the frequency of these biomarkers in Brazilian patients with lung adenocarcinoma (LUAD) are limited, and existing studies predominantly included patients from the southeast region of the country. MATERIALS AND METHODS The goal of this study was to investigate the frequency of somatic mutations in the EGFR, KRAS, NRAS, and BRAF genes, ALK, and PD-L1 expression in a series of Brazilian patients diagnosed with LUAD predominantly recruited from centers in southern Brazil. Molecular analysis of the EGFR, KRAS, NRAS, and BRAF genes was performed by next-generation sequencing using DNA extracted from tumor tissue. Immunohistochemistry was used to detect ALK and PD-L1 expression. RESULTS Analysis of 619 tumors identified KRAS mutations in 189 (30.2%), EGFR mutations in 120 (19.16%), and BRAF mutations in 19 (3%). Immunohistochemistry demonstrated ALK and PD-L1 expression in 4% and 35.1% of patients, respectively. CONCLUSION To our knowledge, this is the first study investigating the molecular epidemiology of patients with LUAD from southern Brazil and the largest assessing the frequency of multiple predictive biomarkers for this tumor in the country. The study also reveals a distinct mutation profile compared with data originating from other regions of Brazil. |
id |
UFRGS-2_8bf8d229b310fd916fad60c5d7371884 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/232208 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Andreis, Tiago FingerCorrêa, Bruno da SilveiraVianna, Fernanda Sales LuizParis, Fernanda deSiebert, MarinaLeistner-Segal, SandraHahn, Eriza CristinaUlbrich, Jane MariaOliveira, Francine Hehn deRivero, Luis Fernando da RosaLorandi, ViníciusProlla, Patrícia AshtonMacedo, Gabriel de Souza2021-11-25T04:38:31Z20192378-9506http://hdl.handle.net/10183/232208001133096PURPOSE Adenocarcinoma is the most common histologic subtype of non–small-cell lung cancer, representing 40% of all diagnoses. Several biomarkers are currently used to determine patient eligibility for targeted treatments, including analysis of molecular alterations in EGFR and ALK, as well as programmed death-ligand 1 (PD-L1) protein expression. Epidemiologic data reporting the frequency of these biomarkers in Brazilian patients with lung adenocarcinoma (LUAD) are limited, and existing studies predominantly included patients from the southeast region of the country. MATERIALS AND METHODS The goal of this study was to investigate the frequency of somatic mutations in the EGFR, KRAS, NRAS, and BRAF genes, ALK, and PD-L1 expression in a series of Brazilian patients diagnosed with LUAD predominantly recruited from centers in southern Brazil. Molecular analysis of the EGFR, KRAS, NRAS, and BRAF genes was performed by next-generation sequencing using DNA extracted from tumor tissue. Immunohistochemistry was used to detect ALK and PD-L1 expression. RESULTS Analysis of 619 tumors identified KRAS mutations in 189 (30.2%), EGFR mutations in 120 (19.16%), and BRAF mutations in 19 (3%). Immunohistochemistry demonstrated ALK and PD-L1 expression in 4% and 35.1% of patients, respectively. CONCLUSION To our knowledge, this is the first study investigating the molecular epidemiology of patients with LUAD from southern Brazil and the largest assessing the frequency of multiple predictive biomarkers for this tumor in the country. The study also reveals a distinct mutation profile compared with data originating from other regions of Brazil.application/pdfengJournal of global oncology. Alexandria. Vol. 5 (2019), 9 p.PrognósticoBiomarcadoresAdenocarcinoma de pulmãoBrasilAnalysis of predictive biomarkers in patients with lung adenocarcinoma from Southern Brazil reveals a distinct profile from other regions of the countryEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001133096.pdf.txt001133096.pdf.txtExtracted Texttext/plain41469http://www.lume.ufrgs.br/bitstream/10183/232208/2/001133096.pdf.txtcc2971a86e11128895380b8996ca0d96MD52ORIGINAL001133096.pdfTexto completo (inglês)application/pdf759960http://www.lume.ufrgs.br/bitstream/10183/232208/1/001133096.pdf94e49b21ff7e78bc8658abb7b26f1fd0MD5110183/2322082021-12-06 05:43:34.357431oai:www.lume.ufrgs.br:10183/232208Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2021-12-06T07:43:34Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Analysis of predictive biomarkers in patients with lung adenocarcinoma from Southern Brazil reveals a distinct profile from other regions of the country |
title |
Analysis of predictive biomarkers in patients with lung adenocarcinoma from Southern Brazil reveals a distinct profile from other regions of the country |
spellingShingle |
Analysis of predictive biomarkers in patients with lung adenocarcinoma from Southern Brazil reveals a distinct profile from other regions of the country Andreis, Tiago Finger Prognóstico Biomarcadores Adenocarcinoma de pulmão Brasil |
title_short |
Analysis of predictive biomarkers in patients with lung adenocarcinoma from Southern Brazil reveals a distinct profile from other regions of the country |
title_full |
Analysis of predictive biomarkers in patients with lung adenocarcinoma from Southern Brazil reveals a distinct profile from other regions of the country |
title_fullStr |
Analysis of predictive biomarkers in patients with lung adenocarcinoma from Southern Brazil reveals a distinct profile from other regions of the country |
title_full_unstemmed |
Analysis of predictive biomarkers in patients with lung adenocarcinoma from Southern Brazil reveals a distinct profile from other regions of the country |
title_sort |
Analysis of predictive biomarkers in patients with lung adenocarcinoma from Southern Brazil reveals a distinct profile from other regions of the country |
author |
Andreis, Tiago Finger |
author_facet |
Andreis, Tiago Finger Corrêa, Bruno da Silveira Vianna, Fernanda Sales Luiz Paris, Fernanda de Siebert, Marina Leistner-Segal, Sandra Hahn, Eriza Cristina Ulbrich, Jane Maria Oliveira, Francine Hehn de Rivero, Luis Fernando da Rosa Lorandi, Vinícius Prolla, Patrícia Ashton Macedo, Gabriel de Souza |
author_role |
author |
author2 |
Corrêa, Bruno da Silveira Vianna, Fernanda Sales Luiz Paris, Fernanda de Siebert, Marina Leistner-Segal, Sandra Hahn, Eriza Cristina Ulbrich, Jane Maria Oliveira, Francine Hehn de Rivero, Luis Fernando da Rosa Lorandi, Vinícius Prolla, Patrícia Ashton Macedo, Gabriel de Souza |
author2_role |
author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Andreis, Tiago Finger Corrêa, Bruno da Silveira Vianna, Fernanda Sales Luiz Paris, Fernanda de Siebert, Marina Leistner-Segal, Sandra Hahn, Eriza Cristina Ulbrich, Jane Maria Oliveira, Francine Hehn de Rivero, Luis Fernando da Rosa Lorandi, Vinícius Prolla, Patrícia Ashton Macedo, Gabriel de Souza |
dc.subject.por.fl_str_mv |
Prognóstico Biomarcadores Adenocarcinoma de pulmão Brasil |
topic |
Prognóstico Biomarcadores Adenocarcinoma de pulmão Brasil |
description |
PURPOSE Adenocarcinoma is the most common histologic subtype of non–small-cell lung cancer, representing 40% of all diagnoses. Several biomarkers are currently used to determine patient eligibility for targeted treatments, including analysis of molecular alterations in EGFR and ALK, as well as programmed death-ligand 1 (PD-L1) protein expression. Epidemiologic data reporting the frequency of these biomarkers in Brazilian patients with lung adenocarcinoma (LUAD) are limited, and existing studies predominantly included patients from the southeast region of the country. MATERIALS AND METHODS The goal of this study was to investigate the frequency of somatic mutations in the EGFR, KRAS, NRAS, and BRAF genes, ALK, and PD-L1 expression in a series of Brazilian patients diagnosed with LUAD predominantly recruited from centers in southern Brazil. Molecular analysis of the EGFR, KRAS, NRAS, and BRAF genes was performed by next-generation sequencing using DNA extracted from tumor tissue. Immunohistochemistry was used to detect ALK and PD-L1 expression. RESULTS Analysis of 619 tumors identified KRAS mutations in 189 (30.2%), EGFR mutations in 120 (19.16%), and BRAF mutations in 19 (3%). Immunohistochemistry demonstrated ALK and PD-L1 expression in 4% and 35.1% of patients, respectively. CONCLUSION To our knowledge, this is the first study investigating the molecular epidemiology of patients with LUAD from southern Brazil and the largest assessing the frequency of multiple predictive biomarkers for this tumor in the country. The study also reveals a distinct mutation profile compared with data originating from other regions of Brazil. |
publishDate |
2019 |
dc.date.issued.fl_str_mv |
2019 |
dc.date.accessioned.fl_str_mv |
2021-11-25T04:38:31Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/232208 |
dc.identifier.issn.pt_BR.fl_str_mv |
2378-9506 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001133096 |
identifier_str_mv |
2378-9506 001133096 |
url |
http://hdl.handle.net/10183/232208 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Journal of global oncology. Alexandria. Vol. 5 (2019), 9 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/232208/2/001133096.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/232208/1/001133096.pdf |
bitstream.checksum.fl_str_mv |
cc2971a86e11128895380b8996ca0d96 94e49b21ff7e78bc8658abb7b26f1fd0 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225043888308224 |